Compare EJH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EJH | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 3.3M |
| IPO Year | 2019 | 2012 |
| Metric | EJH | RDHL |
|---|---|---|
| Price | $1.21 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 2.6M |
| Earning Date | 05-18-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.50 |
| 52 Week High | $3.07 | $2.61 |
| Indicator | EJH | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 37.60 |
| Support Level | $1.07 | N/A |
| Resistance Level | $1.35 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 39.13 | 12.79 |
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving orders online and providing services offline. Its operations are organized into four reportable segments: appliance installation and maintenance services, housekeeping services, senior care services, and educational consulting services. The company generates the majority of its revenue from installation and maintenance.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.